Brought to you by 
Swedish Orphan to distribute Pharming's Rhucin
12 Aug 2016
Executive Summary
Swedish Orphan Biovitrum has received exclusive rights to distribute fellow rare disease therapeutics developer Pharming Group NV's Rhucin (conestat alfa) in Norway, Iceland, Switzerland, and 24 European Union countries over the next ten years.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Swedish Orphan to distribute Pharming's Rhucin
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice